A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: A gynecologic oncology group study

Steven C. Plaxe; John A. Blessing; George Olt; Nader Husseinzadah; Samuel S. Lentz; Koen DeGeest; Fidel A. Valea

doi:10.1007/s00280-002-0470-2

A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: A gynecologic oncology group study

Steven C. Plaxe, John A. Blessing, George Olt, Nader Husseinzadah, Samuel S. Lentz, Koen DeGeest, Fidel A. Valea

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Purpose: The Gynecologic Oncology Group performed a phase II study to determine the response rate to pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix. Methods: PZA was administered intravenously over 3 h every 3 weeks. A dose of 760 mg/m² was given to the first 11 patients and was reduced to 560 mg/m² for subsequent patients. The dose reduction was undertaken because of unexpected severe neutropenia among the initial patients. Results: Among 24 evaluable patients, 21 of whom had prior chemotherapy, there was one, brief, complete response (4.2%) and no partial responses. The major toxicity was neutropenia. Conclusion: PZA at the dose and schedule employed, has insignificant activity in this population.

Original language	English (US)
Pages (from-to)	151-154
Number of pages	4
Journal	Cancer Chemotherapy and Pharmacology
Volume	50
Issue number	2
DOIs	https://doi.org/10.1007/s00280-002-0470-2
State	Published - 2002
Externally published	Yes

Keywords

Cervical cancer
PZA
Pyrazoloacridine

ASJC Scopus subject areas

Oncology
Toxicology
Pharmacology
Cancer Research
Pharmacology (medical)

Access to Document

10.1007/s00280-002-0470-2

Cite this

@article{d8f366a0ba9744119f9e128f422fb1a1,

title = "A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: A gynecologic oncology group study",

abstract = "Purpose: The Gynecologic Oncology Group performed a phase II study to determine the response rate to pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix. Methods: PZA was administered intravenously over 3 h every 3 weeks. A dose of 760 mg/m2 was given to the first 11 patients and was reduced to 560 mg/m2 for subsequent patients. The dose reduction was undertaken because of unexpected severe neutropenia among the initial patients. Results: Among 24 evaluable patients, 21 of whom had prior chemotherapy, there was one, brief, complete response (4.2%) and no partial responses. The major toxicity was neutropenia. Conclusion: PZA at the dose and schedule employed, has insignificant activity in this population.",

keywords = "Cervical cancer, PZA, Pyrazoloacridine",

author = "Plaxe, {Steven C.} and Blessing, {John A.} and George Olt and Nader Husseinzadah and Lentz, {Samuel S.} and Koen DeGeest and Valea, {Fidel A.}",

note = "Funding Information: Acknowledgements This study was supported by National Cancer Institute grants of the Gynecologic Oncology Group Administrative Office (CA 27469) and the Gynecologic Oncology Group Statistical Office (CA 37517).",

year = "2002",

doi = "10.1007/s00280-002-0470-2",

language = "English (US)",

volume = "50",

pages = "151--154",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Verlag",

number = "2",

}

TY - JOUR

T1 - A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix

T2 - A gynecologic oncology group study

AU - Plaxe, Steven C.

AU - Blessing, John A.

AU - Olt, George

AU - Husseinzadah, Nader

AU - Lentz, Samuel S.

AU - DeGeest, Koen

AU - Valea, Fidel A.

N1 - Funding Information: Acknowledgements This study was supported by National Cancer Institute grants of the Gynecologic Oncology Group Administrative Office (CA 27469) and the Gynecologic Oncology Group Statistical Office (CA 37517).

PY - 2002

Y1 - 2002

N2 - Purpose: The Gynecologic Oncology Group performed a phase II study to determine the response rate to pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix. Methods: PZA was administered intravenously over 3 h every 3 weeks. A dose of 760 mg/m2 was given to the first 11 patients and was reduced to 560 mg/m2 for subsequent patients. The dose reduction was undertaken because of unexpected severe neutropenia among the initial patients. Results: Among 24 evaluable patients, 21 of whom had prior chemotherapy, there was one, brief, complete response (4.2%) and no partial responses. The major toxicity was neutropenia. Conclusion: PZA at the dose and schedule employed, has insignificant activity in this population.

AB - Purpose: The Gynecologic Oncology Group performed a phase II study to determine the response rate to pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix. Methods: PZA was administered intravenously over 3 h every 3 weeks. A dose of 760 mg/m2 was given to the first 11 patients and was reduced to 560 mg/m2 for subsequent patients. The dose reduction was undertaken because of unexpected severe neutropenia among the initial patients. Results: Among 24 evaluable patients, 21 of whom had prior chemotherapy, there was one, brief, complete response (4.2%) and no partial responses. The major toxicity was neutropenia. Conclusion: PZA at the dose and schedule employed, has insignificant activity in this population.

KW - Cervical cancer

KW - PZA

KW - Pyrazoloacridine

UR - http://www.scopus.com/inward/record.url?scp=0036353160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036353160&partnerID=8YFLogxK

U2 - 10.1007/s00280-002-0470-2

DO - 10.1007/s00280-002-0470-2

M3 - Article

C2 - 12172981

AN - SCOPUS:0036353160

SN - 0344-5704

VL - 50

SP - 151

EP - 154

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 2

ER -

A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: A gynecologic oncology group study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this